ライフサイエンスコーパス: alkylating agent

1 N-ethylmaleimide (NEM), a cysteine-selective alkylating agent.

2 lex was more resistant to inactivation by an alkylating agent.

3 e in vitro and confers protection from a DNA-alkylating agent.

4 ivalent requiring metabolic breakdown to the alkylating agent.

5 verse nucleophiles using methylarenes as the alkylating agent.

6 , an imidazotetrazine-class chemotherapeutic alkylating agent.

7 ross a diverse cell line panel exposed to an alkylating agent.

8 sible positions in LacY react well with this alkylating agent.

9 yl trifluoromethanesulfonate as a reversible alkylating agent.

10 icrotubule toxin and a duocarmycin-class DNA-alkylating agent.

11 s as a topoisomerase inhibitor as well as an alkylating agent.

12 ng bromocrotonate as the activated methylene alkylating agent.

13 ine is a newly approved and better-tolerated alkylating agent.

14 m to repair DNA adducts and are sensitive to alkylating agents.

15 e metabolism to form potent DNA minor groove-alkylating agents.

16 otizing scleritis may respond to IMT, mainly alkylating agents.

17 2-diketones using simple terminal olefins as alkylating agents.

18 ses, these compounds convert into active DNA-alkylating agents.

19 ge may protect the active site cysteine from alkylating agents.

20 es, which include ionizing radiation and DNA-alkylating agents.

21 unity and tumor clearance in response to DNA alkylating agents.

22 tion with dexamethasone, anthracyclines, and alkylating agents.

23 ed upon exposure to endogenous and exogenous alkylating agents.

24 ation of ketones using simple alkenes as the alkylating agents.

25 reactive methyl donor, and by reaction with alkylating agents.

26 foci specifically upon exposure of cells to alkylating agents.

27 s an important role by protecting cells from alkylating agents.

28 esistance to certain cancer chemotherapeutic alkylating agents.

29 phenylalanine) and involve Me2Zn or Et2Zn as alkylating agents.

30 arian damage include ovarian irradiation and alkylating agents.

31 was strongly correlated with sensitivity to alkylating agents.

32 f resistance to some cancer chemotherapeutic alkylating agents.

33 sions created by endogenous or environmental alkylating agents.

34 y in clinical trials to enhance therapy with alkylating agents.

35 Mitomycins are bioreductively activated DNA-alkylating agents.

36 gens results in the exposure of DNA to toxic alkylating agents.

37 rine, which results in protection of N7 from alkylating agents.

38 nse of malignant melanoma cells treated with alkylating agents.

39 sed cellular sensitivity to chemotherapeutic alkylating agents.

40 egies that reduce the peripheral toxicity of alkylating agents.

41 rrent chemotherapeutic regimens that include alkylating agents.

42 ation in response to DNA damage caused by O6-alkylating agents.

43 th low AAG protein levels were sensitized to alkylating agents.

44 s (COMCs) to highly reactive exocyclic enone alkylating agents.

45 ator compound for many types of carcinogenic alkylating agents.

46 and can detect both gas- and solution-phase alkylating agents.

47 SCC foci formation and are hypersensitive to alkylating agents.

48 t severe, pulmonary vascular complication of alkylating agents.

49 s makes them significantly more sensitive to alkylating agents.

50 nd intrastrand cross-linking agents, but not alkylating agents.

51 h antimetabolites, T-cell inhibitors, and/or alkylating agents.

52 ylation strategy using simple olefins as the alkylating agents.

53 ersus-host disease regardless of exposure to alkylating agents.

54 poor growth in ARTEMIS deficiency and use of alkylating agents.

55 %) or in association with rituximab (21.1%), alkylating agents (36.8%) or a combination of cyclophosp

56 patients), purine analogs (26 patients), or alkylating agents (39 patients).

57 further modified by the sulfhydryl-specific alkylating agent, 5-fluorescein-maleimide (5FM).

58 ies), including proteasome inhibitors (91%), alkylating agents (91%), autologous stem cell transplant

59 ere treated with RT, and almost 40% received alkylating agent (AA) -containing chemotherapy (predomin

60 Cumulative exposure to alkylating agent (AA) was notably lower in the G studies

61 , we quantified cumulative doses of specific alkylating agents (AAs) and reconstructed radiation dose

62 Exposure of Escherichia coli to alkylating agents activates expression of AidB in additi

63 Compared with temozolomide, a clinical DNA-alkylating agent against glioma, 6OTD required lower con

64 Treatment with alkylating agents also was not significantly associated

65 at G4 targeting of this clinically important alkylating agent alters the overall mechanism of action.

66 Conditioning regimens consisted of an alkylating agent and fludarabine, and GVHD prophylaxis i

67 rate that ALX, through its dual action as an alkylating agent and topoisomerase inhibitor, represents

68 hat the clinical efficacy of combinations of alkylating agents and anthracyclines are due to the abil

69 adiation and treatment with a combination of alkylating agents and anthracyclines.

70 otoxic agent with structural similarities to alkylating agents and antimetabolites, but which is non-

71 onse resulting from DNA crosslinking agents, alkylating agents and camptothecin.

72 esponse to replicative stress induced by DNA alkylating agents and greatly influences drug response i

73 duced by lysosomal injury resulting from DNA alkylating agents and hypotonic shock, whereas it promot

74 ive SCID suggest that minimizing exposure to alkylating agents and ionizing radiation is important fo

75 ne (1-MeA) is formed in DNA by reaction with alkylating agents and naturally occurring methyl halides

76 lites, but which is non-cross-resistant with alkylating agents and other drugs in vitro and in the cl

77 high-dose radiation (especially over 10 Gy), alkylating agents and procarbazine, at older ages, were

78 survival following first-line treatment with alkylating agents and purine analogs.

79 ated with defective apoptosis in response to alkylating agents and purine analogues.

80 articularly those who have been treated with alkylating agents and purine nucleoside analogs and woul

81 plausible cause-effect relationship between alkylating agents and PVOD.

82 ne questionnaire, and quantified exposure to alkylating agents and radiation therapy.

83 We quantified chemotherapy with alkylating agents and radiotherapy doses to the testes a

84 ses and related quaternary ammonium salts as alkylating agents and singlet oxygen sensitizers.

85 compromise fertility, especially exposure to alkylating agents and whole body irradiation, which caus

86 ng adult (CAYA) cancer who were treated with alkylating agents and/or radiation, with potential expos

87 g with two alkylating agents (p=0.015 vs one alkylating agent) and last available pre-HSCT bilirubin

88 itivity of the mutants to hydroxyurea (a DNA-alkylating agent) and UV irradiation.

89 EN), to alkyl diazohydroxides (which are DNA-alkylating agents) and also aldehydes (HCHO from DMN and

90 tients, is associated with prior exposure to alkylating agents, and a high frequency of TP53 loss or

91 istant to conventional (e.g., dexamethasone, alkylating agents, and anthracyclines) or novel (e.g., t

92 r-stable and inexpensive nitroalkanes as the alkylating agents, and delivers synthetically versatile

93 MGMT) in tumor correlates with resistance to alkylating agents, and depletion of MGMT activity can en

94 op1 inhibitors, but also to Top2 inhibitors, alkylating agents, and DNA synthesis inhibitors.

95 trobenzofurazan-based scaffolds, maleimides, alkylating agents, and electrophilic aldehydes, toward c

96 such as exposure to reactive oxygen species, alkylating agents, and many of the antibiotics targeting

97 intestinal cancer associated with exogenous alkylating agents, and that endogenous alkylation does n

98 health-related outcomes, such as exposure to alkylating agents, anthracyclines, radiotherapy, and sur

99 s in Diels-Alder reactions and electrophilic alkylating agents are described.

100 The mutagenic and cytotoxic effects of many alkylating agents are reduced by O(6)-alkylguanine-DNA a

101 uding antimetabolites, T-cell inhibitors and alkylating agents, are effective in many patients, allow

102 Dose escalation of alkylating agents as tested in this trial did not improv

103 The use of an alkene as the formal "alkylating" agent associated with the tolerance for nume

104 Treatment of animals with the alkylating agent azoxymethane resulted in both liver tox

105 erapy with bortezomib, dexamethasone, and an alkylating agent (BDex+AA) is associated with improved b

106 disease can be cured with therapy without an alkylating agent, bleomycin, etoposide, or high-dose, ex

107 N) or CB-839, hypersensitize cancer cells to alkylating agents both in vitro and in vivo.

108 TH-302, a prodrug of the cytotoxic alkylating agent bromo-isophosphoramide mustard, is pref

109 phosphorylbutane (DOB) is a precursor of the alkylating agent but-2-ene-1,4-dial.

110 repair kinetics and increases sensitivity to alkylating agents, but not other forms of DNA damage.

111 poxic microenvironment induces resistance to alkylating agents by activating targets in the mammalian

112 ortant DNA repair protein that protects from alkylating agents by converting O6-alkylguanine to guani

113 om the mutagenic and carcinogenic effects of alkylating agents by removing O(6)-alkylguanine adducts

114 Alkylating agents can induce sustained drug-free remissi

115 ored by depletion of Top1, illustrating that alkylating agents can trigger cytotoxic Top1-breaks.

116 Nitrosoureas, traditionally viewed as DNA alkylating agents, can also covalently modify proteins s

117 more than 50% decrease in the LD(50) for DNA-alkylating agent carmustine (BCNU), which is commonly us

118 10.5-41.6] since diagnosis) who had received alkylating agent chemotherapy but no radiation therapy.

119 Increasing doses of uterine radiation and alkylating agent chemotherapy were strongly associated w

120 ing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities

121 al tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT.

122 ells were more than 10-fold resistant to the alkylating agent cisplatin (CDDP), while trastuzumab coe

123 Given the activity of the lenalidomide-alkylating agent combination in myeloma, we designed thi

124 ients with prior exposure to fludarabine and alkylating agent combinations, and patients with prior e

125 eath induced by cyclophosphamide (CP), a DNA alkylating agent commonly used in chemotherapy.

126 increase in mutations and sensitivity to an alkylating agent compared with the WT hMPG.

127 one alone (control group) concomitantly with alkylating agents containing chemotherapy.

128 s-resistant drugs used for conditioning (eg, alkylating agents) could favor elimination of residual c

129 We report that the combined use of the alkylating agent cyclophosphamide (CTX) and an agonist a

130 -DNA-methyltransferase (MGMT), which repairs alkylating agent damage, is one such target.

131 by alteration of ligation kinetics following alkylating agent damage, leading to interest in combinin

132 a and treatment with N-ethylmaleimide (thiol alkylating agent), dithiothreitol (disulfide reducing ag

133 Those with a summed alkylating agent dose (AAD) score of three or four or wh

134 2; 95% CI, -0.02 to 0.64), higher cumulative alkylating agent dose (AAD) score or treatment with cycl

135 ed with pelvic irradiation and/or increasing alkylating agent doses were at risk for acute ovarian fa

136 ity ensuing from chemotherapy combining O(6)-alkylating agents (e.g., temozolomide) with pseudosubstr

137 propiolate followed by a rearrangement to an alkylating agent, either an acyl halide or a ketene.

138 Direct normoxic PARP1 activation by a DNA alkylating agent enhanced Bnip3 expression, and caused B

139 ta define the dose-specific relation between alkylating agent exposure and semen variables in adult s

140 Alkylating agent exposure was associated with an 8.8-fol

141 Alkylating agent exposure was estimated using the cyclop

142 nt stem cell collection prior to significant alkylating agent exposure, given its potential deleterio

143 abine), 4-6 of 6 matched dUCB-other (n = 40; alkylating agent + fludarabine +/- TBI), and 8 of 8 (n =

144 Trichloroacetimidates are useful alkylating agents for aromatic amines, requiring only a

145 of maximizing the chemotherapeutic value of alkylating agents for cancer treatment.

146 nd their relationship to genotype and use of alkylating agents for conditioning.

147 fter validation of the assay using two model alkylating agents, fractions of an extract of hops (Humu

148 thiol derivatives with Michael acceptors and alkylating agents furnished thioglycosides and (1,1)-thi

149 s underlying the sensitivity of IDE to thiol-alkylating agents has not been elucidated.

150 DNA-alkylating agents have a central role in the curative th

151 that might predict a better response to DNA alkylating agents have been identified in GBMs, except f

152 protects cells from carcinogenic effects of alkylating agents; however, MGMT is silenced by promoter

153 anthracycline (HR, 2.6; 95% CI, 1.6-4.3) or alkylating agents (HR, 1.7; 95% CI, 1.2-2.5), non-breast

154 ed necrotic cell death, induced by cytotoxic alkylating agents, hyperactivation of poly-ADP-ribose po

155 that monomethyl sulfate acts as an efficient alkylating agent in water, reacting spontaneously with o

156 pated and unknown DNA adducts induced by DNA alkylating agents in biological samples.

157 icancer cotherapies, used as enhancements of alkylating agents in chemotherapy.

158 cellular pathways mediating resistance to O6-alkylating agents in glioblastoma cells.

159 erase (MGMT), a key enzyme for resistance to alkylating agents in glioblastoma patients.

160 Due to the abundant presence of alkylating agents in living cells and the environment, D

161 ht alcohols such as ethanol could be used as alkylating agents in this methodology.

162 uggest that the mechanism of cytotoxicity by alkylating agents includes the necessity for homologous

163 and methyl methanesulfonate and longer chain alkylating agents including N-ethyl-N-nitrosourea, ethyl

164 ially increased sensitivity to commonly used alkylating agents, including cisplatin, indicating that

165 severe lesions that can be produced by many alkylating agents, including N-methyl-N'-nitro-N-nitroso

166 Alkylating agents induce cytotoxic DNA base adducts.

167 In wild-type animals DNA alkylating agents induce photoreceptor apoptosis and sev

168 reviously shown in tumor xenografts that DNA alkylating agents induce sporadic cell necrosis and regr

169 confirm the formation of PARP-1 DPCs during alkylating agent-induced base excision repair (BER) and

170 ylase (MPG) dramatically sensitizes cells to alkylating agent-induced cytotoxicity.

171 iosulfonate reagents: MTSET+, MTSES-) and an alkylating agent (iodoacetamide).

172 However, use of preconditioning with alkylating agents is associated with a greater likelihoo

173 of the major cytotoxic lesions generated by alkylating agents is DNA 3-alkyladenine, which can be ex

174 Exclusion of alkylating agents is justified for the most favorable su

175 The benefit of cancer chemotherapy based on alkylating agents is limited because of the action of DN

176 sm may not augment some regionally delivered alkylating agents, leading to a net increase in tumor si

177 under basic conditions in the presence of an alkylating agent leads to atropselective O-alkylation wi

178 Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade gl

179 DNA alkylating agents like nitrogen mustard (NM) are easily

180 reatment following topoisomerase II poisons, alkylating agents, local radiation, hematopoietic stem c

181 Using thiol-alkylating agents, mass spectrometry, and an assay for a

182 cing viability in the face of treatment with alkylating agents (mechlorethamine), anthracylines (doxo

183 e, enhanced active JNK levels, and increased alkylating agent-mediated apoptosis.

184 replication slowing; upon treatment with the alkylating agent methyl methane sulfonate, cds1Delta mut

185 2308 exhibited increased sensitivity to the alkylating agent methyl methanesulfonate (MMS) compared

186 Saccharomyces cerevisiae, resistance to the alkylating agent methyl methanesulfonate (MMS) is mediat

187 leotide resolution in yeast treated with the alkylating agent methyl methanesulfonate (MMS).

188 ar protein reorganization on exposure to the alkylating agent methyl methanesulfonate (MMS).

189 e products that modulate the toxicity of the alkylating agent methyl methanesulfonate (MMS).

190 e was enhanced upon DNA damage caused by the alkylating agent methyl methanesulfonate and that the re

191 RN knockdown cells are hypersensitive to the alkylating agent methyl methanesulfonate, which creates

192 st Saccharomyces cerevisiae treated with the alkylating agent methyl methanesulfonate.

193 arly severe in mutant cells treated with the alkylating agent methyl methanesulfonate.

194 Cellular sensitivity to two monofunctional alkylating agents (methyl methane sulfonate and N-methyl

195 Administration of the DNA-alkylating agent methylazoxymethanol acetate (MAM) on em

196 ssays and potentiate the cytotoxicity of the alkylating agents methylmethane sulfonate and temozolomi

197 to monensin but also to salinomycin and the alkylating agent, methylnitrosourea.

198 induced following exposure to a bifunctional alkylating agent, mitomycin C (MMC), and that the progen

199 ystem, leads to increased sensitivity to the alkylating agent MMS and hyper-recombination in an oligo

200 312 helps to prevent tumour induction by the alkylating agent MNU, which predominantly caused T cell

201 ast to the sensitivity seen to heterogeneous alkylating agents, MPG overexpression generates no cellu

202 The trichloroacetimidate alkylating agent must be a stable cation precursor for t

203 and tested for reactivity with the permeant alkylating agent N-ethylmaleimide in right-side-out memb

204 Here we used the DNA alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine, a

205 h UV radiation and a minimal dose of the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine.

206 r rad50 after exposure to UV-C radiation, an alkylating agent (N-methyl-N'-nitro-N-nitrosoguanidine),

207 All patients received chemotherapy (alkylating agent, n = 23; doxorubicin, n = 16); 22 recei

208 ly accelerated by treatment of mice with the alkylating agent, N-ethyl-N-nitrosourea (ENU), regardles

209 eficient mice were treated with a potent DNA alkylating agent, N-ethyl-nitrosourea (ENU), to induce s

210 e from 20 inbred strains to the prototypical alkylating agent, N-nitroso-N-ethylurea (ENU).

211 eplacements react with the membrane-permeant alkylating agent NEM.

212 The main therapeutic options include alkylating agents, nucleoside analogues, and rituximab.

213 F can be developed to enhance the effects of alkylating agents on cancer cells.

214 o had not had a response to rituximab and an alkylating agent or had had a relapse within 6 months af

215 cing intracellular NAD(+) depletion, such as alkylating agents or direct NAD(+) synthesis inhibitors,

216 phocytic leukemia (CLL) who are treated with alkylating agents or single-agent fludarabine, its signi

217 itivity was not observed upon treatment with alkylating agents or UV irradiation.

218 tive lesions, upon exposure to UV radiation, alkylating agents, or oxidative conditions.

219 multivariate analysis, conditioning with two alkylating agents (p=0.015 vs one alkylating agent) and

220 d after reduction of receptor reserve by the alkylating agent, phenoxybenzamine, as it reduced the ma

221 All patients received alkylating agent plus fludarabine; 792 received allograf

222 cacy compared with corticosteroids alone and alkylating agents plus corticosteroids to achieve comple

223 Although cytotoxic alkylating agents possessing two electrophilic reactive

224 a (WM) and closely related disorders include alkylating agents, purine analogs, and monoclonal antibo

225 agents in WM include monoclonal antibodies, alkylating agents, purine analogs, proteasome inhibitors

226 rgeting of KRAS mutant DNA using a synthetic alkylating agent (pyrrole-imidazole polyamide indole-sec

227 with 100% sperm retrieval while exposure to alkylating agents resulted in a significantly lower sper

228 elative risk [RR], 2.9; 95% CI, 2.1 to 4.2), alkylating agents (RR, 2.2; 95% CI, 1.6 to 3.0), and epi

229 oses of radiation to the ovaries, increasing alkylating agent score, and a diagnosis of Hodgkin's lym

230 Treatment with alkylating agents, second-line therapy, and age older th

231 etic diseases, the use of MTX rather than an alkylating agent such as cyclophosphamide would be prefe

232 Alkylating agents such as temozolomide lose their effica

233 y especially benefit from treatment with DNA alkylating agents such as temozolomide.

234 Chemotherapeutic alkylating agents, such as bifunctional nitrogen mustard

235 Alkylating agents, such as cyclophosphamide, set up the

236 changes color upon the exposure to dangerous alkylating agents, such as iodomethane vapor, without th

237 Chemotherapeutic regimes involving alkylating agents, such as methylators and crosslinking

238 tions to counteract the cytotoxic effects of alkylating agents, such as nitrosoureas, which play a ce

239 S(N)1-alkylating agents, such as the mutagenic and cytotoxic d

240 of bases damaged by oxidative metabolism or alkylating agents, such as those commonly used in cancer

241 ER and enhancing the cytotoxic effect of DNA-alkylating agent Temozolomide (TMZ) in mismatch repair (

242 tant radiation and chemotherapy with the DNA alkylating agent temozolomide (TMZ).

243 udes radiation and chemotherapy with the DNA alkylating agent temozolomide (TMZ).

244 The efficacy of the alkylating agent temozolomide has been attributed to the

245 tic response came from use of the S(N)1-type alkylating agent temozolomide in combination with ionizi

246 The alkylating agent temozolomide, commonly used in the trea

247 evealed that LCA exhibits synergism with the alkylating agent temozolomide, which engages BER through

248 y the proteasome inhibitor bortezomib or the alkylating agent temozolomide.

249 increased invasiveness and resistance to the alkylating agent temozolomide.

250 s glioblastoma-resistant cancer cells to the alkylating agent temozolomide.

251 platin, taxol and tamoxifen but not with the alkylating agents temozolomide (TMZ), carmustine and chl

252 ; tetrachlorobenzoquinone (TCBQ) is a potent alkylating agent that reacts with cellular thiols at a d

253 human lymphoblastoid cells were treated with alkylating agents that have different mechanisms of acti

254 tion damage by protecting DNA and destroying alkylating agents that have yet to reach their DNA targe

255 n the presence of sodium dodecyl sulfate and alkylating agents that irreversibly inhibit Ubl protease

256 Both classes of compound are potent alkylating agents that may need to be considered in futu

257 n has been shown to increase the toxicity of alkylating agents that produce 7-meG adducts, and here w

258 S(N)1-type alkylating agents that produce cytotoxic O(6)-methyl-G (

259 ic fibroblasts are specifically sensitive to alkylating agents that result in O6-methylguanine adduct

260 t is widely accepted that melphalan is a DNA alkylating agent, the mechanism of selective antitumor e

261 proaches with alkyl halides or sulfonates as alkylating agents, the use of unactivated olefins for al

262 encing has been shown to predict response to alkylating agent therapy in selected malignancies.

263 es with increased therapeutic sensitivity to alkylating agent therapy.

264 t cancer, possibly by reacting directly with alkylating agents, thereby preventing DNA damage.

265 of the cobalt complex with 0.75 mol % of the alkylating agent to afford the desired products in up to

266 ucing conditions and then challenged with an alkylating agent to probe solvent accessibility of diffe

267 ent of polymers with methyl iodide (MeI), an alkylating agent, to convert polymer-bound tertiary amin

268 A and R69F mutants are more sensitive toward alkylating agent toxicity, revealing the key role of Arg

269 lthough the gene transcription is induced by alkylating agent treatment, the protein is degraded in v

270 nders them capable of acting as sulfating or alkylating agents under relatively mild conditions.

271 Temozolomide (TMZ) is an oral alkylating agent used for the treatment of high-grade gl

272 od was applied to temozolomide, an important alkylating agent used in the treatment of brain tumors,

273 Temozolomide is a DNA-alkylating agent used to treat brain tumors, but resista

274 MGMT also provides resistance of tumours to alkylating agents used in cancer chemotherapy and its in

275 Oxazaphosphorines are alkylating agents used in routine clinical practices for

276 from the corresponding N-alkyl imidazole, an alkylating agent (usually MeI), and sodium borohydride (

277 n whose mothers were exposed to radiation or alkylating agents versus neither, the prevalence of anom

278 eloped a strategy to harness alkyl amines as alkylating agents via C-N bond activation.

279 on, corticosteroids, and chronic exposure to alkylating agents via distinct molecular routes involvin

280 A adducts based on the reactivity of the DNA alkylating agent was demonstrated by inclusion of an ion

281 An isoxazole-based alkylating agent was developed to selectively alkylate c

282 Exposure to alkylating agents was observed in 83.8% of cases, mostly

283 laromustine (VNP40101M), a sulfonylhydrazine alkylating agent, was conducted in patients age 60 years

284 ch relies on the synthesis of (13)C-enriched alkylating agents, was applied to the production of 15-r

285 ins play a role in the biological effects of alkylating agents, we inactivated the gene, referred to

286 teine hydrolases, being inactivated by thiol alkylating agents, while being insensitive to inhibition

287 oma cells to apoptosis following exposure to alkylating agents, while not affecting primary melanocyt

288 Cyclophosphamide (CPA) is a DNA alkylating agent widely used in cancer chemotherapy.

289 le mice with melphalan (MLP), a bifunctional alkylating agent widely used in chemotherapy, induces DN

290 Bendamustine hydrochloride is an alkylating agent with novel mechanisms of action.

291 oretazine (VNP40101M) is a sulfonylhydrazine alkylating agent with significant antileukemia activity.

292 4-(p-nitrobenzyl)pyridine (NBP), a trap for alkylating agents with nucleophilic characteristics simi

293 re susceptible to bi- and tri-functional DNA alkylating agents with this phenotype readily complement

294 o interest in combining AGT inhibitors or O6-alkylating agents with topoisomerase I inhibitors.

295 nd alkylating toxins, we reacted a series of alkylating agents with varied classes of oxo compounds (

296 no optimal approach that uses standard dose-alkylating agents without significant late effects.

297 st the hypothesis that increased exposure to alkylating agents would be associated with decreased spe

298 s, a mild protocol using simple and abundant alkylating agents would have considerable use in the syn

299 an catalyze the hydrolysis of the potent DNA-alkylating agents yatakemycin (YTM) and CC-1065.

300 yes/no), radiation to the neck (yes/no), and alkylating agent (yes/no).